| Drug General Information |
| Drug ID |
D0OZ2S
|
| Former ID |
DIB020200
|
| Drug Name |
Lck inhibitor
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C23H22N4O
|
| InChI |
InChI=1S/C23H22N4O/c24-22-21-20(14-27(17-6-4-5-7-17)23(21)26-15-25-22)16-10-12-19(13-11-16)28-18-8-2-1-3-9-18/h1-3,8-15,17H,4-7H2,(H2,24,25,26)
|
| InChIKey |
FMETVQKSDIOGPX-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
11111001, 11646370, 15326282, 17405013, 24278409, 26759040, 39998441, 43223589, 47796121, 50106230, 50106231, 53183244, 53777556, 53800712, 56463495, 85230986, 87235821, 90341305, 92303890, 99302714, 103227491, 103990403, 114636931, 121361306, 124749726, 124800078, 124879781, 124879782, 127867300, 128321599, 136132792, 139200427, 162163949, 162247946, 163124447, 163564404, 163687809, 170482576, 175613790, 178102625, 178126263, 179235874, 204370260, 208013267, 208264928, 208265648, 226709716, 252451196
|
| Target and Pathway |
| Target(s) |
Lck tyrosine kinase |
Target Info |
Inhibitor |
[2]
|
|---|
|
KEGG Pathway
|
NF-kappa B signaling pathway
|
|
Osteoclast differentiation
|
|
Natural killer cell mediated cytotoxicity
|
|
T cell receptor signaling pathway
|
|
HTLV-I infection
|
|
Primary immunodeficiency
|
|
NetPath Pathway
|
TCR Signaling Pathway
|
|
IL2 Signaling Pathway
|
|
PANTHER Pathway
|
Parkinson disease
|
|
T cell activation
|
|
Pathway Interaction Database
|
Atypical NF-kappaB pathway
|
|
Glypican 1 network
|
|
TCR signaling in naï
|
|
Signaling events mediated by PTP1B
|
|
IL12-mediated signaling events
|
|
Regulation of p38-alpha and p38-beta
|
|
TCR signaling in naï
|
|
Thromboxane A2 receptor signaling
|
|
SHP2 signaling
|
|
IL2-mediated signaling events
|
|
CXCR4-mediated signaling events
|
|
Class I PI3K signaling events
|
|
IL2 signaling events mediated by PI3K
|
|
amb2 Integrin signaling
|
|
EPHA forward signaling
|
|
PDGFR-beta signaling pathway
|
|
IL2 signaling events mediated by STAT5
|
|
Ephrin B reverse signaling
|
|
Alpha-synuclein signaling
|
|
Reactome
|
GPVI-mediated activation cascade
|
|
PIP3 activates AKT signaling
|
|
Regulation of KIT signaling
|
|
Phosphorylation of CD3 and TCR zeta chains
|
|
Translocation of ZAP-70 to Immunological synapse
|
|
Generation of second messenger molecules
|
|
PECAM1 interactions
|
|
Constitutive Signaling by Aberrant PI3K in Cancer
|
|
DAP12 signaling
|
|
CD28 co-stimulation
|
|
CD28 dependent PI3K/Akt signaling
|
|
CD28 dependent Vav1 pathway
|
|
CTLA4 inhibitory signaling
|
|
PD-1 signaling
|
|
Interleukin-2 signaling
|
|
WikiPathways
|
Notch Signaling Pathway
|
|
Interferon type I signaling pathways
|
|
IL-2 Signaling Pathway
|
|
Inflammatory Response Pathway
|
|
Signaling by SCF-KIT
|
|
DAP12 interactions
|
|
Host Interactions of HIV factors
|
|
PIP3 activates AKT signaling
|
|
T-Cell Receptor and Co-stimulatory Signaling
|
|
B Cell Receptor Signaling Pathway
|
|
TSLP Signaling Pathway
|
|
TCR signaling
|
|
Costimulation by the CD28 family
|
| References |
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6003). |
|---|
| REF 2 | Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of lck II. Bioorg Med Chem Lett. 2000 Oct 2;10(19):2171-4. |
|---|
